Table 1.
Authors | Year | Oesophageal cancer type | Total n | MMRdef n (%) | MSI-High n (%) | Method |
---|---|---|---|---|---|---|
TCGA [24] | 2017 | SqC | 90 | NI | 0 | PCR |
AdC | 70 | 0 | ||||
undiff | 2 | 0 | ||||
Pandilla et al.[57] | 2013 | SqC | 60 | NI | 6 (10) | PCR |
AdC | 30 | 2 (7) | ||||
Farris et al.[38] | 2011 | SqC | 76 | 5 (7) | 5 (7) | IHC, PCR |
Vasavi et al.[44] | 2010 | SqC | 45 | NI | 12 (27) | PCR |
AdC | 5 | 1 (20) | ||||
Matsumoto et al.[58] | 2007 | SqC | 62 | NI | 5 (8) | PCR |
Falkenback et al.[48] | 2005 | AdC | 59 | 2 (3) | 2 (3) | IHC, PCR |
Naidoo et al.[59] | 2005 | SqC | 100 | NI | 5 (5)a | PCR |
Uehara et al.[23] | 2005 | SqC | 122 | 49 (40) | 6 (5)a | IHC |
Evans et al.[47] | 2004 | AdC | 27 | 6 (22) | 0 | IHC, PCR |
Araki et al.[45] | 2004 | SqC | 100 | NI | 0 | PCR |
Hayashi et al.[60] | 2003 | SqC | 30 | NI | 1 (3) | PCR |
Ikeguchi et al.[46] | 1999 | SqC | 20 | NI | 1 (5)a | PCR |
Wu et al.[61] | 1998 | SqC | 92 | NI | 5 (5)a | PCR |
Muzeau et al.[43] | 1997 | SqC | 20 | NI | 0 | PCR |
AdC | 26 | 0 | ||||
Gleeson et al.[62] | 1996 | AdC | 17 | NI | 1 (17) | PCR |
Keller et al.[63] | 1995 | AdC | 15 | NI | 2 (13)a | PCR |
Ogasawara et al.[64] | 1995 | SqC | 35 | NI | 21 (60)a | PCR |
Meltzer et al.[65] | 1994 | SqC | 42 | NI | 1 (2)a | PCR |
AdC | 36 | 2 (6)a |
Abbreviations: AdC, adenocarcinoma; SqC, squamous cell carcinoma; MMRdef, mismatch repair deficiency; MSI, microsatellite instability; PCR, polymerase chain reaction; IHC, immunohistochemistry; NI, not investigated; undiff, undifferentiated.
no distinction made between MSI-High and MSI-Low.